Charles River Laboratories International, Inc. (NYSE:CRL) Shares Bought by Assetmark Inc.

Assetmark Inc. raised its position in Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 5,099.5% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 9,775 shares of the medical research company's stock after acquiring an additional 9,587 shares during the quarter. Assetmark Inc.'s holdings in Charles River Laboratories International were worth $1,804,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently bought and sold shares of the business. Principal Financial Group Inc. grew its holdings in shares of Charles River Laboratories International by 3.6% in the third quarter. Principal Financial Group Inc. now owns 60,501 shares of the medical research company's stock valued at $11,917,000 after purchasing an additional 2,126 shares in the last quarter. Covestor Ltd increased its position in shares of Charles River Laboratories International by 40.9% during the third quarter. Covestor Ltd now owns 327 shares of the medical research company's stock worth $65,000 after acquiring an additional 95 shares during the period. Venturi Wealth Management LLC raised its stake in shares of Charles River Laboratories International by 61.3% in the third quarter. Venturi Wealth Management LLC now owns 1,616 shares of the medical research company's stock valued at $318,000 after acquiring an additional 614 shares in the last quarter. WCM Investment Management LLC raised its stake in shares of Charles River Laboratories International by 33.3% in the third quarter. WCM Investment Management LLC now owns 10,367 shares of the medical research company's stock valued at $2,056,000 after acquiring an additional 2,589 shares in the last quarter. Finally, Apollon Wealth Management LLC purchased a new position in Charles River Laboratories International in the third quarter valued at $201,000. 98.91% of the stock is currently owned by hedge funds and other institutional investors.

Remove Ads

Analyst Ratings Changes

A number of equities analysts have recently commented on CRL shares. Robert W. Baird lowered their price objective on Charles River Laboratories International from $177.00 to $173.00 and set a "neutral" rating for the company in a research report on Thursday, February 20th. JPMorgan Chase & Co. dropped their target price on Charles River Laboratories International from $175.00 to $165.00 and set a "neutral" rating on the stock in a report on Thursday, February 20th. Barclays lowered their price objective on Charles River Laboratories International from $205.00 to $166.00 and set an "equal weight" rating for the company in a research report on Tuesday, February 18th. The Goldman Sachs Group cut their target price on Charles River Laboratories International from $220.00 to $190.00 and set a "buy" rating on the stock in a research report on Thursday, January 23rd. Finally, CLSA downgraded Charles River Laboratories International from a "hold" rating to an "underperform" rating and set a $164.00 price target for the company. in a report on Monday, November 18th. One analyst has rated the stock with a sell rating, fifteen have assigned a hold rating and one has issued a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and an average target price of $198.36.

Charles River Laboratories International Stock Performance

Shares of NYSE CRL traded up $4.34 during midday trading on Friday, reaching $171.27. 1,033,768 shares of the company were exchanged, compared to its average volume of 709,529. The stock has a market cap of $8.76 billion, a P/E ratio of 1,141.78, a PEG ratio of 4.54 and a beta of 1.45. Charles River Laboratories International, Inc. has a 1 year low of $150.79 and a 1 year high of $274.77. The stock has a fifty day simple moving average of $168.35 and a 200 day simple moving average of $185.07. The company has a current ratio of 1.41, a quick ratio of 1.14 and a debt-to-equity ratio of 0.65.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last announced its earnings results on Wednesday, February 19th. The medical research company reported $2.66 earnings per share for the quarter, beating the consensus estimate of $2.50 by $0.16. Charles River Laboratories International had a return on equity of 14.69% and a net margin of 0.52%. The company had revenue of $1 billion for the quarter, compared to the consensus estimate of $983.63 million. During the same period last year, the business posted $2.46 EPS. The company's revenue was down 1.1% on a year-over-year basis. On average, research analysts forecast that Charles River Laboratories International, Inc. will post 9.36 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Charles River Laboratories International news, COO Birgit Girshick bought 1,514 shares of the company's stock in a transaction on Thursday, February 20th. The shares were bought at an average price of $164.63 per share, for a total transaction of $249,249.82. Following the transaction, the chief operating officer now owns 55,058 shares of the company's stock, valued at approximately $9,064,198.54. This trade represents a 2.83 % increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO James C. Foster purchased 6,075 shares of Charles River Laboratories International stock in a transaction dated Thursday, February 20th. The stock was acquired at an average cost of $165.01 per share, with a total value of $1,002,435.75. Following the completion of the acquisition, the chief executive officer now directly owns 183,639 shares in the company, valued at approximately $30,302,271.39. This trade represents a 3.42 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 1.30% of the stock is owned by insiders.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).